Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
| Revenue (TTM) | $95.42M |
| Gross Profit (TTM) | $83.06M |
| EBITDA | $-1.46M |
| Operating Margin | 8.22% |
| Return on Equity | 0.47% |
| Return on Assets | -0.89% |
| Revenue/Share (TTM) | $2.64 |
| Book Value | $3.50 |
| Price-to-Book | 4.79 |
| Price-to-Sales (TTM) | 6.20 |
| EV/Revenue | 5.1 |
| EV/EBITDA | 294.18 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 20.60% |
| Shares Outstanding | $34.70M |
| Float | $28.78M |
| % Insiders | 8.09% |
| % Institutions | 51.78% |
Volatility is currently expanding
If you are looking for stocks that are well positioned to maintain their recent uptrend, Delcath Systems (DCTH) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Delcath Systems, Inc. (DCTH) Q2 2026 Earnings Call Transcript
Delcath Systems NASDAQ: DCTH reported second-quarter 2026 revenue of $29.1 million, up from $24.2 million a year earlier, as growth in HEPZATO KIT sales supported continued commercial expansion and investment in clinical programs beyond metastatic uveal melanoma.
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to earnings of $0.07 per share a year ago.
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the Canaccord Genuity 46th Annual Growth Conference on Tuesday, August 11, 2026, in Boston, MA. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver c.
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on August 6, 2026, at 8:30 AM Eastern Time to discuss results for its second quarter ended June 30, 2026. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, August 6, 202.
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either May 2026 or June 2026. The grants, in the form of Restricted Stock Units (RSUs), totaled 17,000 s.
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy in its global Phase 2 clinical trial evaluating HEPZATO in combination with standard of care (SOC) treatment for liver-dominant metastatic breast cancer (mBC). The Phase 2 trial (DELUMA; NCT06875128) will evalua.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DCTH and any ticker you trade — then tracks every position and per-strategy win rate.
